Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AZ, Lilly's BACE Inhibitor Clears Safety Hurdle And Raises Class Hopes

This article was originally published in Scrip

Executive Summary

AstraZeneca and Eli Lilly are to plough straight ahead with the Phase III part of the AMARANTH study testing their oral beta secretase cleaving enzyme (BACE) inhibitor AZD3293 in early Alzheimer's after an encouraging interim safety review, building confidence in this potential disease-modifying drug class.


Related Content

Lilly CEO ‘Encouraged’ By Trump Meeting As Volume – Not Prices – Drives 4Q Revenue Growth
Bullish Lilly Adds New Alzheimer's Candidate To Clinical Portfolio
After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD
AstraZeneca’s Business Development Head Grady Outlines Strategy Mix
Eisai Parades Pipeline Before Investors During First US R&D Day
Lilly Executes Growth Strategy As New Products Drive Sales Gains





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts